BenQ Medical Technology Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for BenQ Medical Technology.
Wichtige Informationen
n/a
Wachstumsrate der Gewinne
n/a
EPS-Wachstumsrate
Medical Equipment Gewinnwachstum | 23.0% |
Wachstumsrate der Einnahmen | n/a |
Zukünftige Eigenkapitalrendite | n/a |
Analystenabdeckung | None |
Zuletzt aktualisiert | n/a |
Jüngste Aktualisierungen zum künftigen Wachstum
Keine Aktualisierungen
Recent updates
There's Been No Shortage Of Growth Recently For BenQ Medical Technology's (GTSM:4116) Returns On Capital
Apr 07Estimating The Fair Value Of BenQ Medical Technology Corporation (GTSM:4116)
Mar 23BenQ Medical Technology's (GTSM:4116) Shareholders Are Down 49% On Their Shares
Mar 08Does BenQ Medical Technology Corporation (GTSM:4116) Have A Place In Your Dividend Stock Portfolio?
Feb 17BenQ Medical Technology (GTSM:4116) Seems To Use Debt Quite Sensibly
Jan 29BenQ Medical Technology Corporation's (GTSM:4116) Stock Been Rising But Financials Look Weak: Should Shareholders Be Worried?
Jan 11The Returns At BenQ Medical Technology (GTSM:4116) Provide Us With Signs Of What's To Come
Dec 24BenQ Medical Technology's (GTSM:4116) Shareholders Are Down 72% On Their Shares
Dec 07Should You Buy BenQ Medical Technology Corporation (GTSM:4116) For Its 4.4% Dividend?
Nov 17In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da BenQ Medical Technology jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.
Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.
Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
6/30/2024 | 4,597 | 126 | 264 | 407 | N/A |
3/31/2024 | 4,546 | 115 | 315 | 422 | N/A |
12/31/2023 | 4,543 | 115 | 303 | 442 | N/A |
9/30/2023 | 4,506 | 101 | 194 | 353 | N/A |
6/30/2023 | 4,467 | 98 | 300 | 457 | N/A |
3/31/2023 | 4,816 | 115 | 354 | 493 | N/A |
12/31/2022 | 4,377 | 180 | 403 | 483 | N/A |
9/30/2022 | 3,624 | 169 | 307 | 372 | N/A |
6/30/2022 | 2,885 | 143 | 186 | 214 | N/A |
3/31/2022 | 1,748 | 112 | 154 | 178 | N/A |
12/31/2021 | 1,465 | 29 | 88 | 121 | N/A |
9/30/2021 | 1,455 | 48 | 117 | 164 | N/A |
6/30/2021 | 1,445 | 54 | 142 | 196 | N/A |
3/31/2021 | 1,432 | 59 | 100 | 155 | N/A |
12/31/2020 | 1,401 | 62 | 109 | 151 | N/A |
9/30/2020 | 1,349 | 54 | 32 | 63 | N/A |
6/30/2020 | 1,331 | 59 | 58 | 83 | N/A |
3/31/2020 | 1,348 | 63 | 111 | 131 | N/A |
12/31/2019 | 1,380 | 75 | 148 | 169 | N/A |
9/30/2019 | 1,370 | 80 | 205 | 238 | N/A |
6/30/2019 | 1,331 | 77 | 158 | 191 | N/A |
3/31/2019 | 1,307 | 82 | 126 | 159 | N/A |
12/31/2018 | 1,233 | 67 | 88 | 126 | N/A |
9/30/2018 | 1,154 | 55 | -1 | 28 | N/A |
6/30/2018 | 1,144 | 49 | -24 | 46 | N/A |
3/31/2018 | 1,085 | 45 | N/A | 63 | N/A |
12/31/2017 | 1,037 | 47 | N/A | 73 | N/A |
9/30/2017 | 985 | 44 | N/A | 116 | N/A |
6/30/2017 | 901 | 42 | N/A | 99 | N/A |
3/31/2017 | 871 | 43 | N/A | 58 | N/A |
12/31/2016 | 876 | 46 | N/A | 71 | N/A |
9/30/2016 | 922 | 23 | N/A | 87 | N/A |
6/30/2016 | 913 | 22 | N/A | 63 | N/A |
3/31/2016 | 925 | 115 | N/A | 59 | N/A |
12/31/2015 | 938 | 118 | N/A | 86 | N/A |
9/30/2015 | 951 | 149 | N/A | 50 | N/A |
6/30/2015 | 1,022 | 167 | N/A | 95 | N/A |
3/31/2015 | 1,046 | 82 | N/A | 126 | N/A |
12/31/2014 | 1,015 | 78 | N/A | 104 | N/A |
9/30/2014 | 945 | 69 | N/A | 131 | N/A |
6/30/2014 | 869 | 57 | N/A | 116 | N/A |
3/31/2014 | 806 | 43 | N/A | 115 | N/A |
12/31/2013 | 806 | 42 | N/A | 114 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: Insufficient data to determine if 4116's forecast earnings growth is above the savings rate (1%).
Ertrag vs. Markt: Insufficient data to determine if 4116's earnings are forecast to grow faster than the TW market
Hohe Wachstumserträge: Insufficient data to determine if 4116's earnings are expected to grow significantly over the next 3 years.
Einnahmen vs. Markt: Insufficient data to determine if 4116's revenue is forecast to grow faster than the TW market.
Hohe Wachstumseinnahmen: Insufficient data to determine if 4116's revenue is forecast to grow faster than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Insufficient data to determine if 4116's Return on Equity is forecast to be high in 3 years time